Nir Salomon
Jump to navigation
Jump to search
 | The topic of this article may not meet Wikitia's general notability guideline. |
Nir Salomon | |
|---|---|
| Add a Photo | |
| Born | 1978 (age 45–46) Boston |
| Occupation |
|
Nir Salomon (born 1978) is an integrative gastroenterology specialist, researcher, co-founder & Chief of R&D at Evinature, and founder and director of Sheba Hospital’s Integrative Gastroenterology Unit[1].
Salomon was born in Boston and raised in Jerusalem. He is best known for leading research programs for the development of neutraceutical treatments for ulcerative colitis, namely CurQD.[2]
Clinical and medical fields of interest
After completing his studies in Traditional Chinese medicine (TCM) in Israel he studied under Prof. Liang Chao, head of the gastroenterology department at the Chengdu University Hospital of TCM.
Publications
- Lang, A., Salomon, N., Ben-Horin, S., etc. (2015), "Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial". Clinical Gastroenterology and Hepatology.[3]
- Yanai H, Salomon N, Lahat A. (2016) "Complementary Therapies in Inflammatory Bowel Diseases. Curr Gastroenterol Rep.[4]
- Yanai H, Salomon N, Ben-Horin S, Kopylov U. (2023) "Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study." Aliment Pharmacol Ther.[5]
- Ben-Horin S, Salomon N, Kopylov U., etc. (2023) "Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial." Clin Gastroenterol Hepatoly.[6]
References
- ↑ "SHEBA STUDY OFFERS BREAKTHROUGH IN PLANT-BASED ULCERATIVE COLITIS TREATMENT". sheba-global.com (Press release). February 14, 2023.
- ↑ "Israel: Sheba Medical Center touts plant-based treatment for Ulcerative Colitis". i24NEWS.
- ↑ A, Lang; N, Salomon; Jc, Wu; U, Kopylov; A, Lahat; O, Har-Noy; Jy, Ching; Pk, Cheong; B, Avidan; D, Gamus; I, Kaimakliotis; R, Eliakim; Sc, Ng; S, Ben-Horin (August 2, 2015). "Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial". Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 13 (8). doi:10.1016/j.cgh.2015.02.019. PMID 25724700 – via pubmed.ncbi.nlm.nih.gov.
- ↑ Yanai, Henit; Salomon, Nir; Lahat, Adi (December 2, 2016). "Complementary Therapies in Inflammatory Bowel Diseases". Current Gastroenterology Reports. 18 (12): 62. doi:10.1007/s11894-016-0537-6. PMID 27747459 – via PubMed.
- ↑ Yanai, Henit; Salomon, Nir; Lahat, Adi; Ungar, Bella; Eliakim, Rami; Kriger-Sharabi, Ofra; Reiss-Mintz, Hilla; Koslowsky, Benjamin; Shitrit, Ariella Bar-Gil; Tamir-Degabli, Natalie; Dotan, Iris; Zittan, Eran; Maharshak, Nitsan; Hirsch, Ayal; Ben-Horin, Shomron; Kopylov, Uri (July 2, 2023). "Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study". Alimentary Pharmacology & Therapeutics. 58 (2): 175–181. doi:10.1111/apt.17538. PMID 37157131 – via PubMed.
- ↑ Ben-Horin, Shomron; Salomon, Nir; Karampekos, Georgios; Viazis, Nikos; Lahat, Adi; Ungar, Bella; Eliakim, Rami; Kuperstein, Rafael; Kriger-Sharabi, Ofra; Reiss-Mintz, Hilla; Yanai, Henit; Dotan, Iris; Zittan, Eran; Maharshak, Nitsan; Hirsch, Ayal; Weitman, Michal; Mantzaris, Gerassimos J.; Kopylov, Uri (June 9, 2023). "Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial". Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association: S1542–3565(23)00445–7. doi:10.1016/j.cgh.2023.05.023. PMID 37302449 – via PubMed.
External links
This article "Nir Salomon" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.